← Back to Clinical Trials
Recruiting NCT06659146

NCT06659146 Thermotherapy in Addition to SOC Palliative Radiotherapy

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06659146
Status Recruiting
Phase
Sponsor King's College London
Condition Head and Neck Squamous Cell Carcinoma
Study Type INTERVENTIONAL
Enrollment 60 participants
Start Date 2024-10-14
Primary Completion 2028-03-01

Trial Parameters

Condition Head and Neck Squamous Cell Carcinoma
Sponsor King's College London
Study Type INTERVENTIONAL
Phase N/A
Enrollment 60
Sex ALL
Min Age 18 Years
Max Age N/A
Start Date 2024-10-14
Completion 2028-03-01
Interventions
Superficial hyperthermia

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

This study aims to investigate the efficacy and safety profile of superficial hyperthermia (wIRA) in addition to standard of care (SOC) palliative radiotherapy in patients with inoperable/incurable locally advanced or recurrent/metastatic HNSCC or cutaneous SCC superficial tumours not suitable for radical treatment. The investigators will assess the best objective response rate (ORR) of patients with Inoperable/incurable or recurrent/metastatic HNSCC or cSCC with superficial lesion(s) treated with the combination of superficial hyperthermia (wIRA) and palliative radiotherapy.

Eligibility Criteria

Inclusion Criteria: 1. Patient with histologically confirmed incurable or inoperable cancers with disease \[at least one superficial lesion(s) or lymph node(s)\] suitable for hydrosun® TWH1500 treatment 2. Patient undergoing standard of care palliative radiotherapy (suitable with the pre-specified dose and fractionation in the protocol 3. Aged ≥18 years old 4. Eastern Cooperative Oncology Group (ECOG) performance status 0 to 1 5. Patient with capacity to consent Exclusion Criteria: 1. No superficial tumour lesion or lymph node that is suitable for hydrosun® TWH1500 treatment. 2. Patients are not suitable for one of the pre-specified palliative radiotherapy dose and fractionation 3. Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the study.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology